Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Dynavax Technologies Corp (NASDAQ:DVAX)

9.60
Delayed Data
As of Jul 21
 +0.05 / +0.52%
Today’s Change
3.20
Today|||52-Week Range
17.50
+143.04%
Year-to-Date
3 Biotech Stocks on Readers' Minds
Jul 19 / TheStreet.com - Paid Partner Content
Options Traders Expect Huge Moves in Dynavax Technologies (DVAX) Stock
Jul 11 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close9.55
Today’s open9.65
Day’s range9.45 - 9.85
Volume1,124,340
Average volume (3 months)1,366,662
Market cap$525.6M
Dividend yield--
Data as of 4:00pm ET, 07/21/2017

Growth & Valuation

Earnings growth (last year)+10.15%
Earnings growth (this year)+36.87%
Earnings growth (next 5 years)--
Revenue growth (last year)+172.67%
P/E ratioNM
Price/Sales13.77
Price/Book4.15

Competitors

 Today’s
change
Today’s
% change
SCMPSucampo Pharmaceutic...+0.05+0.46%
ITCIIntra-Cellular Thera...-0.29-2.25%
CTMXCytomX Therapeutics ...+0.19+1.42%
CARACara Therapeutics In...-0.11-0.71%
Data as of 4:00pm ET, 07/21/2017

Financials

Next reporting dateJuly 26, 2017
EPS forecast (this quarter)-$0.45
Annual revenue (last year)$11.0M
Annual profit (last year)-$112.4M
Net profit margin-1,018.24%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Eddie J. Gray
Senior Vice President-Operations &
Quality
David F. Novack
Corporate headquarters
Berkeley, California

Forecasts